Question 1

What does peer-reviewed research say about these claims?

Accepted Answer

Bro translation: Mainstream medical consensus does not support the claim that 'lingering mycotoxins' cause chronic illness after mold remediation, nor does it validate the use of peptides like BPC-157 or KPV for treating Mold Illness or MCAS; these are experimental therapies with no FDA approval or robust clinical evidence for these conditions. The assertion that 'cutting-edge lab testing' can reliably find 'root causes' of complex systemic illness is also unsupported by standard-of-care guidelines, which often rely on established diagnostic criteria rather than unvalidated functional panels.

Question 2

Are Jaban M Moore's credentials legitimate?

Accepted Answer

The subject inflates their authority by using a trademarked, unregulated title ('Functional Medicine Expert') to imply they can diagnose and treat complex systemic diseases (mold, MCAS) that are outside the scope of most non-MD/DO licenses. Stated credentials: none detected. Likely credentials: Chiropractor (DC), DC. Credential inflation detected, a white coat is not the same as an MD/DO license.

Question 3

Is Dr Jaban M Moore a real medical doctor?

Accepted Answer

Jaban M Moore is not identified as an MD/DO physician in reviewed credentials or public registry data. Likely credential: Chiropractor (DC).

Question 4

Does Jaban M Moore use False Authority?

Accepted Answer

Uses a trademarked, unregulated title to imply a level of medical authority and expertise that is not recognized by state medical boards, conflating a niche philosophy with board-certified competence. Likely motive: To bypass skepticism about non-MD/DO credentials by creating a proprietary, authoritative brand identity.

Question 5

Does Jaban M Moore use Fear Mongering?

Accepted Answer

Suggests that standard remediation is insufficient and that 'hidden' exposures are the inevitable cause of continued sickness, creating anxiety that only the influencer's specific testing can resolve. Likely motive: To drive patients to purchase expensive, non-standard lab testing panels.

Question 6

Does Jaban M Moore use Sales Funnel Motive?

Accepted Answer

Directly pivots from educational content about complex diseases to a paid consultation link, framing the consultation as the only way to 'uncover the root cause' mentioned in the video. Likely motive: To monetize the anxiety generated by the video content through high-ticket coaching/consulting fees.

Question 7

Is the claim "Peptides such as BPC-157, KPV, thymosin alpha-1, mitochondrial peptides, and low-dose G…" supported by medical literature?

Accepted Answer

High-quality evidence exists that several of the named peptides have anti-inflammatory or immunomodulatory properties, but not specifically in “mold illness,” MCAS, or chronic fatigue syndromes.
For BPC-157, recent narrative reviews and preclinical work show pleiotropic anti-inflammatory and tissue-healing effects in numerous animal models (gut, musculoskeletal, CNS, ischemia‑reperfusion, liver, kidney, lung) and early human pilot data, including phase II work in ulcerative colitis and small pilot studies suggesting tolerability and potential benefit in interstitial cystitis, but these are not targeted at mold illness, MCAS, or chronic fatigue.[11][17]
These data support the concept that BPC-157 may aid tissue repair and reduce inflammation broadly, but they do not provide randomized, indication‑specific evidence for mold toxicity, MCAS, or chronic fatigue.
KPV has preclinical evidence demonstrating suppression of inflammatory signaling (e.g., NF‑κB pathway, p65RelA nuclear translocation) in human bronchial epithelial cells and animal models of colitis, consistent with an anti‑inflammatory role.[12]
Thymosin alpha‑1 has more substantial human evidence: it has been studied in randomized or controlled trials and clinical programs for sepsis, chronic viral infections (e.g., hepatitis), cancer adjunct therapy, and immune modulation, where it can enhance host defenses and modulate inflammatory responses, supporting its use as an immunomodulatory peptide in serious systemic illness, though not specifically in mold illness or MCAS.[18]
Mitochondria‑targeting peptides such as SS‑31 (elamipretide) have undergone phase II trials in conditions like atherosclerotic renal artery stenosis and primary mitochondrial myopathies, with data showing improved renal function, reduced inflammation and oxidative stress, and generally acceptable safety, supporting the idea that mitochondrial peptides can modulate inflammation and cellular stress in specific disease contexts.[14][23]
GLP‑1 receptor agonists have high‑quality evidence (systematic reviews and large clinical trials) demonstrating substantial anti‑inflammatory effects, improvements in metabolic parameters, and reduced cardiovascular risk in diabetes and obesity, and a recent review highlights broad anti‑inflammatory actions with potential implications beyond glycemic control.[19]
Emerging exploratory work and planned RCTs are investigating microdosed GLP‑1–based therapies (e.g., tirzepatide) for long COVID and fatigue symptoms, suggesting scientific interest but not yet definitive proof for chronic fatigue or mold-related conditions.[24]
Overall, the strongest evidence base is for GLP‑1 agonists and thymosin alpha‑1 in defined inflammatory and immune-mediated diseases, and for SS‑31 in mitochondrial and renal vascular disease; BPC‑157 and KPV evidence is largely preclinical with very limited human data. There is essentially no high‑quality randomized trial or guideline-level evidence directly supporting the use of BPC‑157, KPV, thymosin alpha‑1, mitochondrial peptides, or low-dose GLP‑1 therapy specifically for “mold illness,” mast cell activation syndrome (MCAS), or idiopathic chronic fatigue.
The available BPC‑157 literature emphasizes that despite extensive animal data, human evidence is minimal and consists mainly of small pilot studies, with authors explicitly stating that BPC‑157 should be considered investigational and that well‑designed human trials are urgently needed before routine clinical use.[11]
This directly contradicts any implication that BPC‑157 is an established, evidence‑based therapy for chronic fatigue, mold illness, or MCAS.
Similarly, reviews of KPV stress that current research is predominantly preclinical (in vitro and animal models of colitis and barrier function), with no robust clinical trials in MCAS, mold illness, or chronic fatigue syndromes.
For thymosin alpha‑1, while RCTs and clinical studies exist in sepsis, viral infections, and oncology, there is no major guideline or high‑quality RCT endorsing thymosin alpha‑1 for mold toxicity, MCAS, or ME/CFS; existing discussions about possible utility in ME/CFS or long COVID are speculative and emphasize that much more research is needed.
Mitochondrial peptides such as SS‑31 have mixed clinical results: some kidney and Deterministic PubMed cross-check found no matching indexed studies for these terms (absence of indexed evidence is not evidence against the claim). Literature verdict: mixed.

Question 8

Is the claim "Dr. Jill will search for underlying triggers that are contributing to your illness thro…" supported by medical literature?

Accepted Answer

Mainstream medical consensus does not support the claim that 'lingering mycotoxins' cause chronic illness after mold remediation, nor does it validate the use of peptides like BPC-157 or KPV for treating Mold Illness or MCAS; these are experimental therapies with no FDA approval or robust clinical evidence for these conditions. The assertion that 'cutting-edge lab testing' can reliably find 'root causes' of complex systemic illness is also unsupported by standard-of-care guidelines, which often rely on established diagnostic criteria rather than unvalidated functional panels. Evidence lookup unavailable for this claim. Literature verdict: mixed.

Advertised	Verdict
Peptides such as BPC-157, KPV, thymosin alpha-1, mitochondrial peptides, and low-dose GLP-1 therapies are being used to support recovery in patients with mold illness, MCAS, chronic fatigue, and inflammation. Rule: Mo. Rev. Stat. §331.010(1) Missouri law explicitly states chiropractic shall not include "the administration or prescribing of any drug or medicine" or "the practice of medicine," and peptide therapies (including GLP‑1) for systemic conditions constitute drug/medicine use and medical treatment beyond methods taught in chiropractic colleges.[1][4]	Outside scope
Diagnosing and treating systemic autoimmune/neurological conditions (MCAS, Mold Illness) with peptide therapy, which is outside the scope of Naturopathic or Chiropractic licenses. Rule: Mo. Rev. Stat. §331.010(1) Diagnosing and treating systemic autoimmune/neurological diseases with peptide drugs is medical practice and involves administration/prescribing of drugs, which Missouri chiropractic statutes expressly exclude from the chiropractic scope.[1][4]	Outside scope
Peptide therapy for Mold/MCAS Rule: Mo. Rev. Stat. §331.010(1) Providing peptide therapy for mold illness or MCAS is drug-based medical treatment of systemic disease, and Missouri law bars chiropractors from administering or prescribing any drug or medicine or engaging in the practice of medicine.[1][4]	Outside scope
Dr. Jill will search for underlying triggers that are contributing to your illness through cutting-edge lab testing and tailor the intervention to your specific needs as an individual. Rule: Mo. Rev. Stat. §331.010 (20 CSR 2070) Not listed among permitted DC scope activities under the governing practice act.	Outside scope
Listed service Functional Medicine Expert Rule: Mo. Rev. Stat. §331.010(1) Styling oneself as a "functional medicine" expert implies practicing medicine and managing systemic diseases beyond chiropractic adjustment/manipulation, and Missouri law declares chiropractic is not the practice of medicine and excludes the practice of medicine from its scope.[1][4]	Outside scope
Using 'cutting-edge lab testing' to find 'root causes' of complex systemic illness, a practice often outside the scope of non-MD/DO licenses which are limited to specific modalities. Rule: Mo. Rev. Stat. §331.010 (20 CSR 2070) Not listed among permitted DC scope activities under the governing practice act.	Outside scope
Cutting-edge lab testing for root cause Rule: Mo. Rev. Stat. §331.010 (20 CSR 2070) Not listed among permitted DC scope activities under the governing practice act.	Outside scope

Jaban M Moore alias Dr. Peptide Profit

Score breakdown

Key findings

Claims & evidence

Manipulation

Borrowed authority & guest funnel

Host self-funnel

Commerce & grift map

Labs pitched

How the money flows

Sponsors and advertisers

Credentials & scope

Permitted scope vs advertised

What this license permits

Validated associated properties

Analyzed

Funnel routes (third-party)

Tip the jar

Fight disinformation

Log a new mention

Reply snippets

Recent mentions (this doc)

Know someone who can help?

Who should we nudge?

What gets sent

Whambulance

Public challenge log

File a challenge

Citations